JP2022537700A5 - - Google Patents

Info

Publication number
JP2022537700A5
JP2022537700A5 JP2021573830A JP2021573830A JP2022537700A5 JP 2022537700 A5 JP2022537700 A5 JP 2022537700A5 JP 2021573830 A JP2021573830 A JP 2021573830A JP 2021573830 A JP2021573830 A JP 2021573830A JP 2022537700 A5 JP2022537700 A5 JP 2022537700A5
Authority
JP
Japan
Prior art keywords
therapy
inhibitor
administration
survival
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037333 external-priority patent/WO2020252218A1/en
Publication of JP2022537700A publication Critical patent/JP2022537700A/ja
Publication of JP2022537700A5 publication Critical patent/JP2022537700A5/ja
Pending legal-status Critical Current

Links

JP2021573830A 2019-06-12 2020-06-11 細胞媒介細胞傷害性療法と生存促進性bcl2ファミリータンパク質の阻害剤との併用療法 Pending JP2022537700A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860748P 2019-06-12 2019-06-12
US62/860,748 2019-06-12
US201962890594P 2019-08-22 2019-08-22
US62/890,594 2019-08-22
PCT/US2020/037333 WO2020252218A1 (en) 2019-06-12 2020-06-11 Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein

Publications (2)

Publication Number Publication Date
JP2022537700A JP2022537700A (ja) 2022-08-29
JP2022537700A5 true JP2022537700A5 (enExample) 2023-06-20

Family

ID=71950752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573830A Pending JP2022537700A (ja) 2019-06-12 2020-06-11 細胞媒介細胞傷害性療法と生存促進性bcl2ファミリータンパク質の阻害剤との併用療法

Country Status (13)

Country Link
US (1) US20220249637A1 (enExample)
EP (1) EP3983006A1 (enExample)
JP (1) JP2022537700A (enExample)
KR (1) KR20220034782A (enExample)
CN (1) CN114269371A (enExample)
AU (1) AU2020293230A1 (enExample)
BR (1) BR112021024822A2 (enExample)
CA (1) CA3142361A1 (enExample)
IL (1) IL288498A (enExample)
MA (1) MA56206A (enExample)
MX (1) MX2021015317A (enExample)
SG (1) SG11202113356XA (enExample)
WO (1) WO2020252218A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098755A (ko) 2019-11-05 2022-07-12 애브비 인코포레이티드 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘
CA3167134A1 (en) * 2020-02-07 2021-08-12 University Health Network (Uhn) Methods for enhancing t cells using venetoclax
CA3198447A1 (en) * 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022133030A1 (en) * 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US20250195644A1 (en) * 2021-03-05 2025-06-19 Duke University Compositions For and Methods of Preventing Metastases
EP4319750A4 (en) * 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN118055944A (zh) * 2021-08-11 2024-05-17 宾夕法尼亚大学董事会 调节Bcl-2增强嵌合抗原受体癌症免疫疗法功效
CN114414541A (zh) * 2021-12-17 2022-04-29 上海药明生物医药有限公司 一种应用3d细胞成像分析系统检测t细胞杀伤效力的方法
WO2025097150A1 (en) * 2023-11-03 2025-05-08 The University Of Chicago Bcl-2 inhibition to amplify chimeric antigen receptor therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6123655A (en) 1996-04-24 2000-09-26 Fell; Claude Cell separation system with variable size chamber for the processing of biological fluids
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
JP4540754B2 (ja) 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Pcr中のハイブリダイゼーションのモニタリング
US6420108B2 (en) 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
HK1041454B (en) 1998-12-24 2004-12-31 生物安全股份有限公司 Blood separation system particularly for concentrating hematopoietic stem cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
WO2002014555A2 (en) 2000-08-11 2002-02-21 University Of Utah Research Foundation Single-labeled oligonucleotide probes
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097053A2 (en) 2001-05-30 2002-12-05 The Regents Of The University Of Michigan Small molecule antagonists of bcl2 family proteins
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
WO2003038060A2 (en) 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7030115B2 (en) 2002-03-21 2006-04-18 Abbott Laboratories N-sulfonylurea apoptosis promoters
ITCZ20020002A1 (it) 2002-04-11 2003-10-13 Parco Scient E Tecnologico Del Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
ES2345837T3 (es) 2005-03-23 2010-10-04 Biosafe S.A. Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa.
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PL2222861T3 (pl) 2007-12-11 2018-04-30 The University Of North Carolina At Chapel Hill Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
ES2987570T3 (es) 2014-11-05 2024-11-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
BR112017011932A8 (pt) 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療

Similar Documents

Publication Publication Date Title
JP2022537700A5 (enExample)
Morales et al. Role of immunotherapy in Ewing sarcoma
van Duijn et al. CD47/SIRPα axis: bridging innate and adaptive immunity
Luo et al. Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion
JP2022512971A5 (enExample)
Carvalho et al. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
Orentas et al. Immunotherapy targets in pediatric cancer
Wolpoe et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
JP2021501606A5 (enExample)
Weiner et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy
Preston et al. Immunity and immune suppression in human ovarian cancer
JP2019532997A5 (enExample)
Comoli et al. Development of adaptive immune effector therapies in solid tumors
JP2020518591A5 (enExample)
JP2019536460A5 (enExample)
TW201900672A (zh) 改良之抗原結合受體型式
KR20180094922A (ko) 암 치료 방법 및 조성물
WO2017059796A1 (en) Activation and expansion of t cells
Cao et al. Updated clinical perspectives and challenges of chimeric antigen receptor-T cell therapy in colorectal cancer and invasive breast cancer
Wang et al. Immunotherapy resistance in glioblastoma
Jabbari et al. State of the art in immunotherapy of neuroblastoma
Yang et al. Immunotherapy for HER-2 positive breast cancer
Lakhani et al. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
EP3735423A1 (en) Monoclonal antibody neo-201 for the treatment of human carcinomas
Weiner et al. Antibodies and cancer therapy: versatile platforms for cancer immunotherapy